News

The latest from Velocity Clinical Research

Henrik Watz Featured in Free Educational Presentation Available for HCPs on COPD with Type 2 Inflammation

December 4, 2024

Congratulations to Henrik Watz, MD, on his exceptional presentation at the 2024 European Respiratory Society (ERS) ADVENT COPD Symposia! Dr. Watz, Medical Director and Principal Investigator at Velocity Clinical Research in Ahrensburg, Germany, joined Drs. Mona Bafadhel and Alberto Papi for a dynamic discussion, … Read more

Velocity Targets Latin America Expansion with the Appointment of Renata Berardocco as LATAM Managing Director

November 21, 2024

Velocity Clinical Research, the leading fully integrated clinical site organization, announces the appointment of Renata Berardocco as Executive Vice President and Managing Director for the Latin America (LATAM) region. Renata has nearly two decades of experience in senior leadership roles and joins from Fortrea, … Read more

Respiratory Health Priorities are Changing Across Europe – What Role Do Clinical Trial Sites Have to Play?

November 20, 2024

For decades, research into respiratory health has centered on conditions such as asthma and chronic obstructive pulmonary disease (COPD), predominantly because of their high prevalence. However, the incidence of respiratory diseases is increasing globally, with lesser-researched but equally debilitating conditions such as interstitial lung … Read more

Henrick Watz, MD, PhD, Leads Ahrensburg, Germany Site as Top Enroller in Global COPD Trial

November 19, 2024

Another outstanding achievement for Henrik Watz, MD, PhD, and our team in Ahrensburg, Germany! They led enrollment for a global chronic obstructive pulmonary disease (COPD) trial, more than doubling the enrollment of the next highest-performing site. Congratulations to Dr. Watz and our Ahrensburg team! … Read more

Kris Kowdley, MD, Presents Positive Late-Breaking Data for Ipsen’s Iqirvo® at AASLD

November 18, 2024

Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, presented late-breaking data for Iqirvo® (elafibranor), Ipsen’s treatment for primary biliary cholangitis (PBC), at American Association for the Study of Liver Diseases (AASLD). “Over three years, Iqirvo data suggest sustained efficacy and support the safety profile of … Read more

The Start of Germany’s National Pharma Strategy: Implications for CROs and Clinical Trials

November 12, 2024

Over the past decade, Germany’s share of global clinical trial activities has dropped year on year. The country accounted for just 3.9% of trials in 2021, down from 7.2% in 2012. Late last year, the German Government published its National Pharma Strategy, which is … Read more

Velocity Enrolled 8,000+ Participants in Trials in October

November 7, 2024

Velocity enrolled more than 8,000 participants in clinical trials in October, marking our highest-ever enrollment in a single month. This required many long hours and thoughtful solutioning from so many across the organization. A special thank you to our site staff and Recruitment team, … Read more

VISION Technology Contributes to over 7,000 Randomizations Across the U.S. and Europe

October 24, 2024

As of today, VISION technology has now contributed to over 7,000 randomizations across the U.S. and Europe. At just a year since its launch, VISION is already making clinical trials more accessible to all on a global scale. We’re proud of the impact our … Read more

Velocity Named Among the Top 50 Operations Teams at the 2024 OnCon Icon Awards

October 23, 2024

Velocity has been recognized among the Top 50 Operations Teams at the 2024 OnCon Icon Awards! This award is especially meaningful because it’s based on peer and community votes, reflecting the operational excellence our team continues to build as we scale globally. Thank you … Read more

Scaling With a Purpose: Championing the Clinical Trials Sector

October 21, 2024

At the beginning of September, Velocity Clinical Research topped Business North Carolina’s 2024 Fast 40 list. It was our third time receiving the award, which recognizes the fastest-growing mid-market businesses in the state. For a clinical trials organization to achieve this level of scale … Read more

ACRP Article: Providing the Blueprint for Gen AI Adoption in Clinical Trials

October 10, 2024

In his latest article for the Association of Clinical Research Professionals (ACRP), Paul Evans outlines how integrated site organizations can pave the way for AI adoption and generate tangible value for the industry. For sites, investigators, and patients, Gen AI has the potential to … Read more

Closing Trust Gaps: The Economic Case for Enhancing Health Equity in Clinical Trials

October 9, 2024

The pandemic left many notable developments in its wake, not least the increased focus on improving diversity in clinical trials. This issue was thrust into the spotlight during Operation Warp Speed — the accelerated development of a COVID-19 vaccine in the U.S. — and … Read more

Learn more about Velocity's capabilities

Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.

Join a remarkable team doing remarkable work

Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.

Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.

Quality. Continuity. Velocity.